Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.10), Zacks reports.
Lakewood-Amedex Biotherapeutics Stock Down 22.3%
Shares of NASDAQ LABT opened at $0.22 on Tuesday. The firm has a 50-day moving average price of $0.96. Lakewood-Amedex Biotherapeutics has a 52-week low of $0.17 and a 52-week high of $98.20.
Wall Street Analyst Weigh In
A number of research analysts recently commented on the stock. Wall Street Zen downgraded shares of Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 7th. HC Wainwright assumed coverage on shares of Lakewood-Amedex Biotherapeutics in a research report on Wednesday, October 28th. They issued a “buy” rating for the company. Finally, Weiss Ratings raised shares of Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research report on Friday, October 2nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Lakewood-Amedex Biotherapeutics presently has a consensus rating of “Hold”.
Read Our Latest Analysis on LABT
About Lakewood-Amedex Biotherapeutics
Lakewood-Amedex Biotherapeutics is a biotechnology company focused on developing treatments for bacterial infections, including infections caused by drug-resistant pathogens. Its research centers on bisphosphocins, a class of investigational antimicrobial compounds. The company’s activities are primarily research and development; its investigational compounds should not be confused with approved medicines or commercially available products. Publicly available information about its specific product pipeline, operating geographies and leadership is limited.
Read More
- Five stocks we like better than Lakewood-Amedex Biotherapeutics
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
